Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.

House and Senate reports again reference sunscreen but add admonishment that FDA “harmonize its approach with international testing standards.” Item exclusive to House report encourages guidance for drug firms on successfully submitting an application for Rx-to-OTC switch of an oral contraceptive.